|
|
|
|
|
|
|
|
|
|
|
07.08.25 - 22:03
|
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire EN)
|
|
|
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the second quarter ended June 30, 2025, along with key accomplishments and upcoming milestones....
|
|
|
30.07.25 - 13:03
|
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 (GlobeNewswire EN)
|
|
|
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day....
|
|
|
|
|
17.06.25 - 13:03
|
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association′s 85th Scientific Sessions (GlobeNewswire EN)
|
|
|
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association's (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, at the McCormick Place Convention Center in Chicago, Illinois....
|
|
|
|
|
22.05.25 - 13:03
|
Skye Bioscience to Participate in Upcoming Investment Conferences (GlobeNewswire EN)
|
|
|
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:...
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.25 - 13:03
|
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 (GlobeNewswire EN)
|
|
|
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th....
|
|
|
26.04.25 - 02:09
|
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
14.04.25 - 13:03
|
Skye Bioscience to Conduct Meetings at Piper Sandler Conference (GlobeNewswire EN)
|
|
|
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
